NO332262B1 - Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser - Google Patents

Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser Download PDF

Info

Publication number: NO332262B1
Authority: NO; Norway
Prior art keywords: temperature; piroxicam; solution; drying; cyclodextrin
Prior art date: 2002-06-17

Application number

NO20040601A

Other languages

English (en)

Norwegian (no)

Other versions

NO20040601L (no

Inventor

Andrea Capocchi

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-17

Filing date

2004-02-10

Publication date

2012-08-13

2004-02-10 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2004-02-10 Publication of NO20040601L publication Critical patent/NO20040601L/no

2012-08-13 Publication of NO332262B1 publication Critical patent/NO332262B1/no

Links

QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 40
229960002702 piroxicam Drugs 0.000 title claims abstract description 40
238000000034 method Methods 0.000 title claims abstract description 38
229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 25
150000001875 compounds Chemical class 0.000 title claims abstract description 12
238000002360 preparation method Methods 0.000 title claims abstract description 11
230000008569 process Effects 0.000 title abstract description 10
239000001116 FEMA 4028 Substances 0.000 title abstract 2
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title abstract 2
235000011175 beta-cyclodextrine Nutrition 0.000 title abstract 2
229960004853 betadex Drugs 0.000 title abstract 2
238000001035 drying Methods 0.000 claims abstract description 15
230000008014 freezing Effects 0.000 claims abstract description 14
238000007710 freezing Methods 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
238000001816 cooling Methods 0.000 claims description 13
238000004108 freeze drying Methods 0.000 claims description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
239000008187 granular material Substances 0.000 claims description 3
239000000908 ammonium hydroxide Substances 0.000 claims 2
230000001105 regulatory effect Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
239000000126 substance Substances 0.000 abstract description 4
239000007864 aqueous solution Substances 0.000 abstract description 3
229960000074 biopharmaceutical Drugs 0.000 abstract description 2
239000000243 solution Substances 0.000 description 19
238000004090 dissolution Methods 0.000 description 10
229940097362 cyclodextrins Drugs 0.000 description 8
239000003826 tablet Substances 0.000 description 8
238000010521 absorption reaction Methods 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
230000005496 eutectics Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000005280 amorphization Methods 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
238000010668 complexation reaction Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
206010013935 Dysmenorrhoea Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010065016 Post-traumatic pain Diseases 0.000 description 2
238000001237 Raman spectrum Methods 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000009471 action Effects 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000000859 sublimation Methods 0.000 description 2
230000008022 sublimation Effects 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010053155 Epigastric discomfort Diseases 0.000 description 1
238000005079 FT-Raman Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010036313 Post-traumatic headache Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
244000309464 bull Species 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
-1 cyclic oligosaccharides Chemical class 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
238000001938 differential scanning calorimetry curve Methods 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000003507 refrigerant Substances 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000003746 solid phase reaction Methods 0.000 description 1
238000003836 solid-state method Methods 0.000 description 1
238000010671 solid-state reaction Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Plural Heterocyclic Compounds (AREA)

NO20040601A 2002-06-17 2004-02-10 Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser NO332262B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02013251A EP1374906B1 (de)	2002-06-17	2002-06-17	Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe
PCT/EP2003/006142 WO2003105906A1 (en)	2002-06-17	2003-06-12	A process for the preparation of piroxicam: b-cyclodextrin inclusion compounds

Publications (2)

Publication Number	Publication Date
NO20040601L NO20040601L (no)	2004-02-10
NO332262B1 true NO332262B1 (no)	2012-08-13

Family

ID=29716770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040601A NO332262B1 (no)	2002-06-17	2004-02-10	Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser

Country Status (26)

Country	Link
US (1)	US7700579B2 (de)
EP (2)	EP1374906B1 (de)
KR (1)	KR101079484B1 (de)
CN (1)	CN100352444C (de)
AT (1)	ATE359827T1 (de)
AU (1)	AU2003245931A1 (de)
CA (1)	CA2489708A1 (de)
CY (1)	CY1107693T1 (de)
DE (1)	DE60219609T2 (de)
ES (1)	ES2286177T3 (de)
HR (1)	HRP20041192B1 (de)
IL (1)	IL165797A0 (de)
JO (1)	JO2533B1 (de)
MA (1)	MA27367A1 (de)
MX (1)	MXPA04012502A (de)
MY (1)	MY134691A (de)
NO (1)	NO332262B1 (de)
PL (1)	PL218414B1 (de)
PT (1)	PT1374906E (de)
RU (1)	RU2316350C2 (de)
SA (1)	SA03240220B1 (de)
SI (1)	SI1374906T1 (de)
TN (1)	TNSN04245A1 (de)
TW (1)	TWI341731B (de)
WO (1)	WO2003105906A1 (de)
ZA (1)	ZA200410142B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2260871B1 (de)	2004-04-01	2013-05-15	Pierre Fabre Medicament	Einschlusskomplexe enthaltend Piroxicam, ein Cyclodextrin und Arginin
FR2868315B1 (fr) *	2004-04-01	2006-07-14	Pierre Fabre Medicament Sa	Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
FR2876911B1 (fr) *	2004-10-21	2007-04-13	Pierre Fabre Medicament Sa	Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine
CN101002782B (zh) *	2007-01-10	2010-05-19	南京师范大学	含有头孢呋辛酯环糊精包合物的药物组合物及其制备方法
CN101264087B (zh) *	2007-03-14	2010-10-27	南京师范大学	含有头孢泊肟酯环糊精包合物的药物组合物及其制备方法
EP3459533A1 (de)	2010-08-04	2019-03-27	Grünenthal GmbH	Darreichungsform mit 6'-fluor-(n-methyl- oder n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexan-1,1'-pyrano[3,4,b]indol]-4-amin zur behandlung von nozizeptivem schmerz
WO2013004462A1 (en)	2011-07-01	2013-01-10	Fondazione Istituto Insubrico Di Ricerca Per La Vita	A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof
US20130310435A1 (en)	2012-05-18	2013-11-21	Gruenenthal Gmbh	Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) *	2012-05-18	2016-04-12	Gruenenthal Gmbh	Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9855286B2 (en)	2012-05-18	2018-01-02	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US8912226B2 (en)	2012-05-18	2014-12-16	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320729B2 (en)	2012-05-18	2016-04-26	Gruenenthal Gmbh	Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en)	2012-05-18	2013-11-21	Gruenenthal Gmbh	Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1196033B (it) *	1984-02-22	1988-11-10	Chiesi Farma Spa	Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
IT1204725B (it) *	1987-06-17	1989-03-10	Edmond Pharma Srl	Complessi di inclusione del dipiridamolo con ciclodestrine
WO1991013100A1 (en) *	1990-03-02	1991-09-05	Australian Commercial Research & Development Limited	Cyclodextrin compositions and methods for pharmaceutical and industrial applications
US5164379A (en) *	1991-07-15	1992-11-17	Bristol-Myers Company	Sucralfate/cyclodextrin complexes
IT1269578B (it) *	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
DE19922572A1 (de) *	1999-05-17	2000-11-23	Bayer Ag	Verfahren zur Reinigung von organischen Isocyanaten, die so gereinigten organischen Isocyanate und ihre Verwendung

2002
- 2002-06-17 AT AT02013251T patent/ATE359827T1/de active
- 2002-06-17 SI SI200230568T patent/SI1374906T1/sl unknown
- 2002-06-17 ES ES02013251T patent/ES2286177T3/es not_active Expired - Lifetime
- 2002-06-17 DE DE60219609T patent/DE60219609T2/de not_active Expired - Lifetime
- 2002-06-17 EP EP02013251A patent/EP1374906B1/de not_active Expired - Lifetime
- 2002-06-17 PT PT02013251T patent/PT1374906E/pt unknown
2003
- 2003-06-12 RU RU2004136988/15A patent/RU2316350C2/ru active
- 2003-06-12 PL PL373873A patent/PL218414B1/pl unknown
- 2003-06-12 US US10/516,945 patent/US7700579B2/en not_active Expired - Lifetime
- 2003-06-12 KR KR1020047008384A patent/KR101079484B1/ko not_active Expired - Lifetime
- 2003-06-12 HR HRP20041192AA patent/HRP20041192B1/hr not_active IP Right Cessation
- 2003-06-12 WO PCT/EP2003/006142 patent/WO2003105906A1/en not_active Ceased
- 2003-06-12 EP EP03738016A patent/EP1513556B1/de not_active Expired - Lifetime
- 2003-06-12 CN CNB038173565A patent/CN100352444C/zh not_active Expired - Lifetime
- 2003-06-12 MX MXPA04012502A patent/MXPA04012502A/es active IP Right Grant
- 2003-06-12 CA CA002489708A patent/CA2489708A1/en not_active Abandoned
- 2003-06-12 AU AU2003245931A patent/AU2003245931A1/en not_active Abandoned
- 2003-06-15 JO JO200367A patent/JO2533B1/en active
- 2003-06-16 MY MYPI20032243A patent/MY134691A/en unknown
- 2003-06-16 TW TW092116236A patent/TWI341731B/zh not_active IP Right Cessation
- 2003-07-27 SA SA03240220A patent/SA03240220B1/ar unknown
2004
- 2004-02-10 NO NO20040601A patent/NO332262B1/no not_active IP Right Cessation
- 2004-12-10 TN TNP2004000245A patent/TNSN04245A1/en unknown
- 2004-12-15 ZA ZA200410142A patent/ZA200410142B/xx unknown
- 2004-12-16 IL IL16579704A patent/IL165797A0/xx unknown
- 2004-12-17 MA MA28012A patent/MA27367A1/fr unknown
2007
- 2007-07-09 CY CY20071100907T patent/CY1107693T1/el unknown

Also Published As

Publication number	Publication date
HK1080720A1 (en)	2006-05-04
NO20040601L (no)	2004-02-10
EP1513556A1 (de)	2005-03-16
RU2004136988A (ru)	2005-06-10
HRP20041192A2 (en)	2005-08-31
EP1374906B1 (de)	2007-04-18
TWI341731B (en)	2011-05-11
EP1374906A1 (de)	2004-01-02
PL373873A1 (en)	2005-09-19
KR101079484B1 (ko)	2011-11-03
MY134691A (en)	2007-12-31
ES2286177T3 (es)	2007-12-01
DE60219609D1 (de)	2007-05-31
MXPA04012502A (es)	2005-02-24
PT1374906E (pt)	2007-07-24
TW200400043A (en)	2004-01-01
TNSN04245A1 (en)	2007-03-12
ZA200410142B (en)	2006-02-22
US20060135473A1 (en)	2006-06-22
DE60219609T2 (de)	2008-01-03
CY1107693T1 (el)	2013-04-18
EP1513556B1 (de)	2008-08-13
SA03240220B1 (ar)	2007-07-31
WO2003105906A1 (en)	2003-12-24
JO2533B1 (en)	2010-09-05
AU2003245931A1 (en)	2003-12-31
US7700579B2 (en)	2010-04-20
WO2003105906A8 (en)	2004-03-04
PL218414B1 (pl)	2014-12-31
CN1671419A (zh)	2005-09-21
ATE359827T1 (de)	2007-05-15
MA27367A1 (fr)	2005-06-01
RU2316350C2 (ru)	2008-02-10
SI1374906T1 (sl)	2007-10-31
CA2489708A1 (en)	2003-12-24
KR20050008642A (ko)	2005-01-21
CN100352444C (zh)	2007-12-05
IL165797A0 (en)	2006-01-15
HRP20041192B1 (hr)	2013-09-30

Legal Events

Date	Code	Title	Description
2023-07-10	MK1K	Patent expired

Publication	Publication Date	Title
TWI237024B (en)	2005-08-01	A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor
JP5017103B2 (ja)	2012-09-05	薬剤共結晶組成物および関連した使用方法
DK2870163T3 (en)	2018-10-29	PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMIN AND AMINO ACIDS, METHOD OF PREPARING AND USING THEREOF
EP2355805B1 (de)	2019-02-13	Rifaximinkomplexe
US7700579B2 (en)	2010-04-20	Process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
Jaafar et al.	2020	Preparation and physicochemical characterization of cocrystals for enhancing the dissolution rate of glimepiride
WO1995032737A1 (en)	1995-12-07	Pharmaceutical composition
EP1793862B1 (de)	2011-03-23	Verfahren zur herstellung einer piroxicam:beta-cyclodextrin-einschlussverbindung
HUP0204005A2 (hu)	2003-03-28	Pravastatin-nátrium új módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US8492423B2 (en)	2013-07-23	Pharmaceutical propylene glycol solvate compositions
HK1080720B (en)	2008-07-25	A process for the preparation of piroxicam:b-cyclodextrin inclusion compounds
Aragón-Aburto et al.	2022	Characterization, stability and solubility of co-amorphous systems of glibenclamide and L-arginine at different pH.
Thakur et al.	2025	Preparation Techniques of Pharmaceutical Cocrystals
Pandya et al.	2017	Formulation development of fast dispersible tablet of cefuroxime axetil
MXPA00001713A (en)	2001-05-17	New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
KR20130010524A (ko)	2013-01-29	무정형 이트라코나졸의 제조방법